Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Chief Financial Officer | October 06, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Relay Therapeutics, Inc.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,134 |
Last balance in matching sequence
After 2026-10-06 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-10-06 · Sale · Disposed 17,511 · Balance 105,340 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2: This transaction was executed in multiple trades at prices ranging from $18.20 to $19.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 6,538 shares underlying restricted stock units. Row 2 · 2026-10-06 · Sale · Disposed 206 · Balance 105,134 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F4: This transaction was executed in multiple trades at prices ranging from $19.20 to $19.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 6,538 shares underlying restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $18.20 to $19.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 6,538 shares underlying restricted stock units.
F4: This transaction was executed in multiple trades at prices ranging from $19.20 to $19.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 8, 2026 21:29 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 206 | $19.26 | $3,967.56 |
DisclosureSEC source: 0001193125-26-418094 · ownership.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,134 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $19.20 to $19.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 6,538 shares underlying restricted stock units. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 21:29 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 17,511 | $18.58 | $325,354.38 |
DisclosureSEC source: 0001193125-26-418094 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,340 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.20 to $19.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 6,538 shares underlying restricted stock units. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 20:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 17,717 | $18.94 | $335,559.98 |
DisclosureSEC source: 0001193125-26-386464 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,851 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.34 to $19.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 6,538 shares underlying restricted stock units. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 20:16 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 17,717 | $19.74 | $349,733.58 |
DisclosureSEC source: 0001193125-26-355493 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,568 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.51 to $19.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 6,538 shares underlying restricted stock units. Read SEC document |
| July 28, 2026 Filed Jul 30, 2026 20:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,459 | $18.61 | $27,151.99 |
DisclosureSEC source: 0001193125-26-326144 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,285 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 3,269 shares of restricted stock units ("RSUs") on July 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 6,538 shares underlying RSUs. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:07 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 17,717 | $18.69 | $331,130.73 |
DisclosureSEC source: 0001193125-26-298679 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,744 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.39 to $19.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 9,807 shares underlying restricted stock units. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 51,560 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0001193125-26-281061 · ownership.xml · derivative · entry 10 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 223,440 Underlying: Common Stock · 51,560 shares Expires 2035-01-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F7 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 10, 2025, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 61,563 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001193125-26-281061 · ownership.xml · derivative · entry 9 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,563 shares Expires 2030-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F6 · derivative.exercise_date: On March 2, 2020, the reporting person was granted an option to purchase 63,363 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 15,841 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 47,522 shares, vested in sixteen (16) equal quarterly installments following March 11, 2021. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 56,323 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001193125-26-281061 · ownership.xml · derivative · entry 8 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,323 shares Expires 2029-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F5 · derivative.exercise_date: The shares underlying this stock option vested in sixteen (16) equal quarterly installments following the vesting commencement date of April 23, 2019. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 51,560 | $16.97 | $874,973.20 |
DisclosureSEC source: 0001193125-26-281061 · ownership.xml · nonDerivative · entry 7 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,461 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 9,807 shares underlying restricted stock units. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 51,560 | $4.45 | $229,442.00 |
DisclosureSEC source: 0001193125-26-281061 · ownership.xml · nonDerivative · entry 6 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 229,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F3 · balance_after: Includes 9,807 shares underlying restricted stock units. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 61,563 | $16.97 | $1,044,724.11 |
DisclosureSEC source: 0001193125-26-281061 · ownership.xml · nonDerivative · entry 5 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,461 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 9,807 shares underlying restricted stock units. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 61,563 | $5.22 | $321,358.86 |
DisclosureSEC source: 0001193125-26-281061 · ownership.xml · nonDerivative · entry 4 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 239,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F3 · balance_after: Includes 9,807 shares underlying restricted stock units. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 56,323 | $16.97 | $955,801.31 |
DisclosureSEC source: 0001193125-26-281061 · ownership.xml · nonDerivative · entry 3 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,461 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 9,807 shares underlying restricted stock units. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 56,323 | $5.04 | $283,867.92 |
DisclosureSEC source: 0001193125-26-281061 · ownership.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 233,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F3 · balance_after: Includes 9,807 shares underlying restricted stock units. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 17,717 | $17.01 | $301,366.17 |
DisclosureSEC source: 0001193125-26-281061 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,461 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.38 to $17.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 9,807 shares underlying restricted stock units. Read SEC document |
| May 14, 2026 Filed May 14, 2026 22:44 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 17,717 | $12.86 | $227,840.62 |
DisclosureSEC source: 0001193125-26-224545 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 195,178 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.67 to $13.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 9,807 shares underlying restricted stock units. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 20:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 972 | $14.79 | $14,375.88 |
DisclosureSEC source: 0001193125-26-197419 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,895 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 3,268 shares of restricted stock units ("RSUs") on April 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 9,807 shares underlying RSUs. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 00:55 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,800 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001193125-26-150044 · ownership.xml · derivative · entry 4 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,563 Underlying: Common Stock · 1,800 shares Expires 2030-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F4 · derivative.exercise_date: On March 2, 2020, the reporting person was granted an option to purchase 63,363 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 15,841 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 47,522 shares, vested in sixteen (16) equal quarterly installments following March 11, 2021. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 00:55 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,800 | $15.00 | $27,000.00 |
DisclosureSEC source: 0001193125-26-150044 · ownership.xml · nonDerivative · entry 3 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,867 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F3 · balance_after: Includes 13,075 shares underlying restricted stock units. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 00:55 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 1,800 | $5.22 | $9,396.00 |
DisclosureSEC source: 0001193125-26-150044 · ownership.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F3 · balance_after: Includes 13,075 shares underlying restricted stock units. Read SEC document |
| April 07, 2026 Filed Apr 10, 2026 00:55 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 17,717 | $13.01 | $230,498.17 |
DisclosureSEC source: 0001193125-26-150044 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,867 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.42 to $13.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 13,075 shares underlying restricted stock units. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:30 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 17,717 | $10.06 | $178,233.02 |
DisclosureSEC source: 0001193125-26-102270 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 231,584 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $9.77 to $10.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 13,075 shares underlying restricted stock units. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 21:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,695 | $8.45 | $14,322.75 |
DisclosureSEC source: 0001193125-26-029403 · ownership.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,301 F3 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,724 shares of RSUs on January 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F4 · balance_after: Includes 13,075 shares underlying RSUs. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 13,820 | $7.62 | $105,308.40 |
DisclosureSEC source: 0001193125-26-029403 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,996 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,394 shares of restricted stock units ("RSUs") on January 26, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 18,799 shares underlying RSUs. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:12 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001193125-26-014106 · ownership.xml · derivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2036-01-12 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 13, 2026, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 21,664 | $7.29 | $157,930.56 |
DisclosureSEC source: 0001193125-25-258574 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,631 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 48,115 shares of restricted stock units ("RSUs") on October 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 110,008 shares underlying RSUs. Read SEC document |
| July 29, 2025 Filed Jul 30, 2025 20:54 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 18,380 | $3.68 | $67,638.40 |
DisclosureSEC source: 0000950170-25-100366 · ownership.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,295 F3 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,393 shares of RSUs on July 28, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F4 · balance_after: Includes 158,123 shares underlying RSUs. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:54 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,701 | $3.74 | $6,361.74 |
DisclosureSEC source: 0000950170-25-100366 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,675 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,724 shares of restricted stock units ("RSUs") on July 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 200,516 shares underlying RSUs. Read SEC document |
| April 30, 2025 Filed May 1, 2025 00:24 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 12,943 | $3.00 | $38,829.00 |
DisclosureSEC source: 0000950170-25-061366 · ownership.xml · nonDerivative · entry 4 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 355,376 F4 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,392 shares of RSUs on April 29, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F5 · balance_after: Includes 206,240 shares underlying RSUs. Read SEC document |
| April 29, 2025 Filed May 1, 2025 00:24 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 3,558 | $3.23 | $11,492.34 |
DisclosureSEC source: 0000950170-25-061366 · ownership.xml · nonDerivative · entry 3 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 368,319 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. F2 · balance_after: Includes 248,632 shares underlying RSUs. Read SEC document |
| April 28, 2025 Filed May 1, 2025 00:24 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 981 | $3.17 | $3,109.77 |
DisclosureSEC source: 0000950170-25-061366 · ownership.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 371,877 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. F2 · balance_after: Includes 248,632 shares underlying RSUs. Read SEC document |
| April 28, 2025 Filed May 1, 2025 00:24 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,709 | $3.17 | $5,417.53 |
DisclosureSEC source: 0000950170-25-061366 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 372,858 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,722 shares of restricted stock units ("RSUs") on April 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 248,632 shares underlying RSUs. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 20:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 4,566 | $2.84 | $12,967.44 |
DisclosureSEC source: 0000950170-25-047725 · ownership.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 374,567 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. F2 · balance_after: Includes 254,354 shares underlying RSUs. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 20:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 298 | $2.84 | $846.32 |
DisclosureSEC source: 0000950170-25-047725 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 379,133 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on March 26, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 254,354 shares underlying RSUs. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 02:10 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 20,791 | $4.42 | $91,896.22 |
DisclosureSEC source: 0000950170-25-011327 · ownership.xml · nonDerivative · entry 5 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 379,431 F6 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 69,570 shares of RSUs on January 29, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F7 · balance_after: Includes 255,346 shares underlying RSUs. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 02:10 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 2,109 | $4.55 | $9,595.95 |
DisclosureSEC source: 0000950170-25-011327 · ownership.xml · nonDerivative · entry 4 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 400,222 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. F5 · balance_after: Includes 324,916 shares underlying RSUs. Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 02:10 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 139,141 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-011327 · ownership.xml · nonDerivative · entry 3 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 402,331 F4 · shares: Represents RSUs granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. F5 · balance_after: Includes 324,916 shares underlying RSUs. Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 02:10 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 2,283 | $4.63 | $10,570.29 |
DisclosureSEC source: 0000950170-25-011327 · ownership.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 263,190 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. F2 · balance_after: Includes 185,775 shares underlying RSUs. Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 02:10 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 33,753 | $4.63 | $156,276.39 |
DisclosureSEC source: 0000950170-25-011327 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 265,473 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 105,723 shares of restricted stock units ("RSUs") on January 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 185,775 shares underlying RSUs. Read SEC document |
| January 10, 2025 Filed Jan 15, 2025 02:00 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0000950170-25-005564 · ownership.xml · derivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2035-01-09 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 10, 2025, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 21:05 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 4,566 | $4.42 | $20,181.72 |
DisclosureSEC source: 0000950170-24-141597 · ownership.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 299,226 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $4.37 to $4.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 291,498 shares underlying RSUs. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 21:05 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 299 | $4.38 | $1,309.62 |
DisclosureSEC source: 0000950170-24-141597 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 303,792 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on December 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 291,498 shares underlying RSUs. Read SEC document |
| October 29, 2024 Filed Oct 30, 2024 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 2,300 | $5.95 | $13,685.00 |
DisclosureSEC source: 0000950170-24-118982 · ownership.xml · nonDerivative · entry 3 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 304,091 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. F2 · balance_after: Includes 292,490 shares underlying RSUs. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 5,105 | $6.06 | $30,936.30 |
DisclosureSEC source: 0000950170-24-118982 · ownership.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 306,391 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. F2 · balance_after: Includes 292,490 shares underlying RSUs. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,697 | $6.06 | $10,283.82 |
DisclosureSEC source: 0000950170-24-118982 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 311,496 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,724 shares of restricted stock units ("RSUs") on October 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 292,490 shares underlying RSUs. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 20:07 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 6,162 | $7.46 | $45,968.52 |
DisclosureSEC source: 0000950170-24-110810 · ownership.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 313,193 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $7.37 to $7.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 298,214 shares underlying RSUs. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 20:07 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 295 | $7.51 | $2,215.45 |
DisclosureSEC source: 0000950170-24-110810 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 319,355 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on September 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 298,214 shares underlying RSUs. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 22:43 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 9,078 | $8.51 | $77,253.78 |
DisclosureSEC source: 0000950170-24-088815 · ownership.xml · nonDerivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 319,650 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $8.22 to $8.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 299,206 shares underlying RSUs. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 22:43 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,702 | $8.85 | $15,062.70 |
DisclosureSEC source: 0000950170-24-088815 · ownership.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 328,728 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,723 shares of restricted stock units ("RSUs") on July 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 299,206 shares underlying RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.